Sarepta Therapeutics, Inc. (SRPT) Stock Analysis
Healthcare · Biotechnology · NasdaqGS
Sarepta Therapeutics, Inc. (SRPT) posted $2.20B in revenue for fiscal 2025 (up 15.6% year over year), with a net loss of $713.41M, and has compounded revenue about 32.4%/yr over five years, per its SEC filings.
Data last refreshed August 2, 2026 from SEC filings · how we compute this
The analyst's take on Sarepta Therapeutics, Inc.
Sarepta Therapeutics, Inc. has grown revenue from $5.42M to $2.20B over the last 10 fiscal years, compounding about 32.4% a year. The most recent year was up 15.6%, so growth has cooled from its longer-run pace.
Net margin sits at -32.5%, down 44.9 points year over year on a 98.8% gross margin. It carries about $828.97M of total debt.
The one thing worth a second look in the filings is share count rising (dilution).
Synthesised from Sarepta Therapeutics, Inc.'s SEC filings — descriptive, not advice. Ask the analyst your own question →
Sarepta Therapeutics, Inc. revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5.42M | $154.58M | $301.03M | $380.83M | $540.10M | $701.89M | $933.01M | $1.24B | $1.90B | $2.20B |
| Gross profit | $5.29M | — | — | — | — | — | — | — | — | $2.17B |
| Net income | $-267.26M | $-50.69M | $-361.92M | $-715.08M | $-554.13M | $-418.78M | $-703.49M | $-535.98M | $235.24M | $-713.41M |
| Net margin | -4930.2% | -32.8% | -120.2% | -187.8% | -102.6% | -59.7% | -75.4% | -43.1% | 12.4% | -32.5% |
Source: Sarepta Therapeutics, Inc. SEC filings (10-K). 17 years of history available in the interactive view.
Sarepta Therapeutics, Inc.: 3 potential red flags in the filings
Patterns in the filed statements worth a second look — computed and cited, not AI guesswork, and not a signal to sell. The kind of thing that hides in a 10-K.
- Share count rising (dilution)Shares outstanding grew 20.5% over 4 years (87.1M → 105M) — existing holders' stakes are being diluted.
- Debt with negative operating cash flowCarries $829M of debt while last year's operating cash flow was negative ($-205.5M).
- Currently unprofitableThe latest fiscal year was a net loss (net margin -32.5%).
Explore 17 years of Sarepta Therapeutics, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track SRPT in your portfolio →
Sarepta Therapeutics, Inc. financial history by metric
Compare Sarepta Therapeutics, Inc. with peers
About Sarepta Therapeutics, Inc.
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene. The company also develops SRP-9003, a gene therapy program for the treatment of LGMD2E; SRP-1001 to selectively target and knockdown DUX4 using RNAi in Phase 1/2a clinical trials; and SRP-1003 for reduction of expression of the DMPK gene in Phase 1/2a clinical trials. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Arrowhead Pharmaceuticals, Inc.; University of Western Australia; Nationwide Children's Hospital; Hansa Biopharma; and Duke University. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
Sarepta Therapeutics, Inc. — frequently asked questions
What is Sarepta Therapeutics, Inc.'s revenue?
Sarepta Therapeutics, Inc. (SRPT) reported revenue of $2.20B for fiscal year 2025, up 15.6% from the prior year, according to its SEC filings.
Is Sarepta Therapeutics, Inc. profitable?
No — SRPT reported a net loss of $-713.41M in fiscal 2025.
What is SRPT's P/E ratio?
Sarepta Therapeutics, Inc. trades at a price-to-earnings ratio of about 43.0 based on the latest data in our nightly-refreshed cache.
How fast is Sarepta Therapeutics, Inc. growing?
SRPT's revenue grew at roughly 32.4% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Sarepta Therapeutics, Inc. have?
As of fiscal year 2025, SRPT carried roughly $828.97M in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Sarepta Therapeutics, Inc.'s gross margin?
SRPT's gross margin was 98.8% in fiscal 2025 — gross profit of $2.17B on revenue of $2.20B.
What is Sarepta Therapeutics, Inc.'s market cap?
Sarepta Therapeutics, Inc. (SRPT) has a market capitalization of about $1.59B, based on the latest data in our nightly-refreshed cache.
When does Sarepta Therapeutics, Inc.'s fiscal year end?
SRPT's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Sarepta Therapeutics, Inc.'s official SEC filings (10-K and 10-Q), covering 17 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.